Evidence map›Paper›PMID 41563072›Full record

ArticleCancer discovery2026

Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.

William C H Cross, Salpie Nowinski, George D Cresswell, Maximilian Mossner, Abhirup Banerjee, Bingxin Lu, Marc J Williams, Georgios Vlachogiannis, Laura J Gay, Ann-Marie Baker and 44 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. A survey of CIN measures across mechanistic models.bioRxiv : the preprint server for biology · 2023
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

54 authors.

William C H Cross *Rare Diseases and Cancer Evolution Lab, Centre for Cancer Research, School of Biological Sciences, University of Reading, Reading, United Kingdom.ORCID 0000-0002-4794-8777
Salpie Nowinski *Centre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-5686-3778
George D Cresswell *Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-3303-068X
Maximilian Mossner *Centre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-9751-3803
Abhirup Banerjee *Centre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-9722-4470
Bingxin Lu *Department of Cell and Developmental Biology, University College London, London, United Kingdom.ORCID 0000-0002-0606-5150
Marc J WilliamsCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-5524-4174
Georgios VlachogiannisCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-3114-8772
Laura J GayCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-9758-8677
Ann-Marie BakerCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-8905-9137
Christopher KimberleyCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-9720-4434
Frederick J H WhitingCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0003-4090-7136
Hayley L Belnoue-DavisDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.ORCID 0000-0003-2914-4932
Pierre MartinezCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-7069-4413
Maria TrakiCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0009-0009-2803-9015
Viola WaltherCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0009-0009-6396-7298
Kane SmithCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-8661-7401
Javier Fernandez-MateosCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-4949-4131
Erika Yara-RomeroCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0009-0002-7557-9128
Erica A OliveiraCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-1624-4021
Salvatore MiliteComputational Biology Research Centre, Human Technopole, Milan, Italy.ORCID 0000-0002-0156-3636
Giulio CaravagnaCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0003-4240-3265
Chela T JamesComputational Biology Research Centre, Human Technopole, Milan, Italy.ORCID 0000-0003-3996-0909
George EliaCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Alison BernerCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-1132-0275
Chang-Ho Ryan ChoiCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-8346-450X
Pradeep RamagiriTumour Profiling Unit (TPU), Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-7677-5916
Ritika ChauhanTumour Profiling Unit (TPU), Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-1224-9343
Nik MatthewsTumour Profiling Unit (TPU), Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-0602-1131
Jamie MurphyDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.ORCID 0000-0003-0519-9031
Anthony AntoniouSt. Mark's Hospital, London, United Kingdom.ORCID 0009-0008-8252-7493
Susan K ClarkDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.ORCID 0000-0002-6929-8082
Miriam MitchisonUCL Hospitals NHS Trust, London, United Kingdom.ORCID 0000-0003-2520-2744
Jo-Anne Chin AleongBarts Health NHS Trust, The Royal London Hospital, London, United Kingdom.ORCID 0000-0002-8942-4250
Enric DomingoDepartment of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-4390-8767
Inmaculada SpiteriCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-1097-8972
Stuart A C McDonaldCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-2386-4915
Darryl ShibataDepartment of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California.ORCID 0000-0002-4567-1639
Miangela M LacléDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-3466-3569
Lai Mun WangWellcome Trust Centre Human Genetics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-7113-4215
Morgan MoorghenSt. Mark's Hospital, London, United Kingdom.ORCID 0000-0003-0262-2674
Ian P M TomlinsonCancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom.
Marco NovelliUCL Cancer Institute, UCL, London, United Kingdom.ORCID 0000-0001-6429-9134
Marnix JansenUCL Cancer Institute, UCL, London, United Kingdom.ORCID 0000-0003-0645-564X
Alan WatsonDepartment of Gastroenterology, Barts Health, Whipps Cross Hospital, London, United Kingdom.ORCID 0009-0003-8233-0459
Nicola ValeriCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-5426-5683
Nicholas A WrightCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0002-5525-3457
John A BridgewaterUCL Cancer Institute, UCL, London, United Kingdom.ORCID 0000-0001-9186-1604
Manuel Rodriguez-JustoUCL Cancer Institute, UCL, London, United Kingdom.ORCID 0000-0001-5007-1761
Chris P BarnesDepartment of Cell and Developmental Biology, University College London, London, United Kingdom.ORCID 0000-0002-9459-1395
Hemant M KocherBarts Health NHS Trust, The Royal London Hospital, London, United Kingdom.ORCID 0000-0001-6771-1905
Simon J LeedhamWellcome Trust Centre Human Genetics, University of Oxford, Oxford, United Kingdom.ORCID 0000-0003-1476-6982
Andrea SottorivaCentre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-6709-9533
Trevor A GrahamCentre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-9582-1597

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
The Role of the Microbiome in Cancer Suppression and Susceptibility Across SpeciesU54CA217376 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MALEY, CARLO, SHIBATA, DARRYL K · 2018 to 2022
$8.6M
Cancer Research UK (CRUK) A19771Cancer Research UK (CRUK) A22745Cancer Research UK (CRUK) A22909Cancer Research UK (CRUK) A26815National Institute for Health and Care Research (NIHR)National Institutes of Health (NIH) CA217376NCI NIH HHS P30 CA008748NCI NIH HHS U54 CA217376Wellcome TrustWellcome Trust (WT) 202778/B/16/Z, 105104/Z/14/ZWellcome Trust (WT) 202778/Z/16/ZWellcome Trust (WT) 206314/Z/17/Z
6 · The paper itself

Abstract

Aneuploidy is near-ubiquitous in cancer and contributes to tumor biology. However, the temporal evolutionary dynamics that select for aneuploidy remain uncharacterized. We performed longitudinal genomic analysis of 755 samples from 167 patients with colorectal-derived neoplasias from different stages through metastasis and treatment. Adenomas had few copy number alterations (CNA) and most were subclonal, whereas cancers had many clonal CNAs, suggesting that progression goes through a CNA bottleneck. Individual colorectal cancer glands from the same tumor had similar karyotypes, despite evidence of ongoing instability at the cell level. CNAs in metastatic lesions, after therapy, and in late recurrences were similar to the primary. Mathematical modeling indicated that these data are consistent with the action of negative selection on CNAs that "trap" cancer genomes on a fitness peak characterized by specific CNAs. Hence, progression to colorectal cancer requires traversing a rugged fitness landscape, whereas subsequent CNA evolution is constrained by negative selection. SIGNIFICANCE: We profiled 167 long-term responders longitudinally (755 samples), documenting long-term cancer evolution. We found that a genetic bottleneck is required for progression and is associated with dramatic increase in CNAs but decrease in clonal diversity. After initiation, copy number evolution is constrained by negative selection through metastasis and treatment. See related commentary by Okada et al., p. 192.

Indexed as

Colorectal NeoplasmsSelection, GeneticAneuploidyDNA Copy Number VariationsHumansKaryotypeNeoplasm Metastasis

Identifiers

PMID41563072
PMCPMC12877747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.